Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy

Phase 1 Study of Autologous Bone Marrow Stem Cells Transplantation in Patients With Temporal Lobe Epilepsy

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00916266

Enrollment

Registered

2009-06-09

Start date

2008-07-31

Completion date

2012-05-31

Last updated

2015-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Keywords

Seizure frequency, Hippocampal volume, Adverse effects

Brief summary

This research investigates the use of autologous bone marrow stem cells for the treatment of medically refractory temporal lobe epilepsy patients.

Detailed description

The aim of this study is to evaluate autologous bone marrow stem cells transplantation as a safe and potentially beneficial treatment for patients with temporal lobe refractory epilepsy. We are mainly evaluating seizure frequency, hippocampal volume an cognitive performance

Interventions

PROCEDUREStem cell transplantation

Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 64 Years

Healthy volunteers

Inclusion criteria

* temporal lobe medically refractory epilepsy patients with hippocampal atrophy

Exclusion criteria

* under 18 or over 65 years old patients * previous neurological surgery * other neurodegenerative diseases

Design outcomes

Primary

Measure	Time frame
seizure frequency	6 months

Secondary

Measure	Time frame
adverse effects	6 months
hippocampal volume	6 months
cognitive performance	6 months

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026